Rare disease

tafamidis, alnylam, bridgebio, pfizer, rare disease, ATTR-CM, market share

Pfizer’s tafamidis faces competition from Alnylam and BridgeBio in rare disease market

Anika Sharma

Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...

BioMarin, Rare disease, pipeline update, Roctavian, gene therapy, hemophilia A, Pipeline addition

BioMarin R&D chief reveals two new pipeline candidates and strategy to sustain innovation

Anika Sharma

BioMarin, the California-based biotech giant, is embarking on a mission to create its most robust pipeline in history, with a ...

Phreesia Acquires MediFind to Enhance Patient Experience and Outcomes

Phreesia Acquires MediFind to Enhance Patient Experience and Outcomes

SG Tylor

Phreesia, a software as a service (SaaS) firm specializing in life sciences and healthcare, has announced its acquisition of MediFind, ...

CDC to review Sanofi’s Beyfortus RSV antibody in August

The CDC vaccination committee has scheduled a date in August to consider using Sanofi, Arizona’s Beyfortus RSV antibody

SG Tylor

Following its highly anticipated FDA approval on Monday, the respiratory syncytial virus (RSV) antibody developed by Sanofi and AstraZeneca is ...

LifeArc's project for rare diseases will spend £100 million on patient care

LifeArc’s project for rare diseases will spend £100 million on patient care

SG Tylor

Source – LifeArc LifeArc, a self-funded non-profit medical research organization and charity, has announced the launch of the Rare Disease ...